Other languages PharmaEssentia Corporation

Equities

6446

TW0006446008

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
428 ^TWD	+0.94%		+2.39%	+23.70%

May. 13	PharmaEssentia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmaEssentia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13
PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	Apr. 26
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia	Apr. 24
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon Alfa-2b) for PV in Brazil	Mar. 28
PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA	Mar. 04
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration	Mar. 04
PharmaEssentia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer	Jan. 24
PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA	Jan. 17
PharmaEssentia Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia	23-10-25
Pharmaessentia Corporation Enters into Exclusive Global License Agreement with Wuxi Biologics for A Myeloid Immune Checkpoint Antibody Candidate	23-10-03
Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B for the Treatment of PV in China	23-09-20
PharmaEssentia Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
PharmaEssentia Corporation announces an Equity Buyback for 4,000,000 shares, for TWD 8,846.64 million.	23-07-28
PharmaEssentia Corporation authorizes a Buyback Plan.	23-07-27
PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as BesremiÂ®) for the Treatment of Patients with Polycythemia Vera (PV)	23-06-30
PharmaEssentia Corporation Selects Pint-Pharma as Commercial Partner for Besremi® (Ropeginterferon Alfa-2B-Njft) in Latin America	23-06-02
PharmaEssentia Corporation announces an Equity Buyback for 5,000,000 shares, representing 1.47% for TWD 8,846.64 million.	23-05-24
PharmaEssentia Corporation authorizes a Buyback Plan.	23-05-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages PharmaEssentia Corporation

Equities

6446

TW0006446008

Other languages

Filters